For more information, visit our product
website www.restasis.com or call 1-866-RESTASIS.

RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only eye drop for patients with keratoconjunctivitis sicca (Chronic Dry Eye) whose tear production may be reduced by ocular inflammation.

RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to occular inflammation associated with Chronic Dry Eye.  Increased tear production was not seen in patients currently using topical steroid drops or tear duct plugs

Chronic Dry Eye is a painful and irritating condition involving abnormalities and deficiencies in the tear film initiated by a variety of causes. Unlike artificial tears, RESTASIS® is the first eye drop believed to effectively treat inflammation, an underlying cause of Dry Eye Disease, rather than temporarily alleviating symptoms.

RESTASIS® should not be used by patients with active infections of the eye, or by patients with known or suspected allergies to any of the ingredients in the formulation. RESTASIS® has not been studied in patients with a history of herpes viral infections of the eye.

The most common side effect experienced by approximately 1 in 5 patients following the use of RESTASIS® ophthalmic emulsion was a burning sensation.